Cancer immunotherapy using checkpoint blockade
2018 · Science · 6,401 citations
https://doi.org/10.1126/science.aar4060
A
Antoni Ribas
APLA Health(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.7K
Papers
162.0K
Citations
158
h-index
534
i10-index
Antoni Ribas is an academic researcher from APLA Health. The author has contributed to research in topics: CAR-T cell therapy research & Cancer Immunotherapy and Biomarkers & Melanoma and MAPK Pathways. The author has an h-index of 158, co-authored 1454 publications.
ORCID: 0000-0003-3669-8458Papers by this author
worksPembrolizumab versus Ipilimumab in Advanced Melanoma
2015 · New England Journal of Medicine · 5,734 citations
https://doi.org/10.1056/nejmoa1503093
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 · Cell · 5,288 citations
https://doi.org/10.1016/j.cell.2017.01.017
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
2014 · New England Journal of Medicine · 4,321 citations
https://doi.org/10.1056/nejmoa1406498
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
2016 · Cell · 3,430 citations
https://doi.org/10.1016/j.cell.2016.02.065
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
2016 · New England Journal of Medicine · 3,062 citations
https://doi.org/10.1056/nejmoa1604958
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat